Perrigo acquires generic Retin-A portfolio

Ireland-incorporated Perrigo (NYSE: PRGO) has said it will acquire a portfolio of generic dosage forms and strengths of Retin-A (tretinoin) from Matawan Pharmaceuticals, a subsidiary of Rouses Point Pharmaceuticals.

Perrigo, which has just escaped from a hostile takeover battle with Mylan (The Pharma Letter November 13), was the authorized generic distributor of these products from 2005 to 2013 before the agreement was terminated. Generic and brand sales of Retin-A, which is indicated for the topical treatment of acne vulgaris, were around $287 million for the 12-months ending October 2015. Additional financial terms were not disclosed.

The company has recently zoned in on acquisitions of generic pharmaceuticals, including Entocort (budesonide), which it agreed to acquire for Anglo-Swedish drugmaker AstraZeneca (LSE: AZN) just last month for $380 million (The Pharma Letter November 23).